RECURRENT NON-SMALL CELL LUNG CANCER
Clinical trials for RECURRENT NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for RECURRENT NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy cocktail aims to boost lung cancer survival
Disease control CompletedThis phase 2 trial tested whether adding relatlimab to the standard immunotherapy nivolumab plus chemotherapy could shrink tumors better in people with advanced or recurrent non-small cell lung cancer. About 468 participants received either the two-immunotherapy combo with chemo …
Matched conditions: RECURRENT NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy shows promise for Hard-to-Treat lung cancer
Disease control CompletedThis early-phase study tested a new drug called ONO-7475 combined with the standard targeted therapy osimertinib in 78 people with advanced EGFR-mutated non-small cell lung cancer. The goal was to see if the combination is safe and tolerable. Participants had stage IIIB, IIIC, IV…
Matched conditions: RECURRENT NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug duo targets lung cancer brain metastases
Disease control CompletedThis phase 2 trial tested two drugs, amivantamab and lazertinib, in 43 adults with a specific type of lung cancer (EGFR-mutant) that had spread to the brain and worsened after previous treatments. The goal was to see if the combination could shrink or control brain tumors. Both d…
Matched conditions: RECURRENT NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC